A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.

An Open-Label Extension Trial Assessing The Safety And Tolerability Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN).

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00353808

Enrollment

112

Registered

2006-07-19

Start date

2006-07-31

Completion date

2007-10-31

Last updated

2011-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

The purpose of this study is to assess the long-term safety and tolerability of \[S,S\]-Reboxetine in patients with chronic pain following shingles. This is the extension study of Protocol A6061026.

Interventions

DRUG[S,S]-Reboxetine

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must have met the patient selection criteria for the preceding double-blind Protocol A6061026 and have completed the 16-week trial. * Patients at screening must have a score of \>/=40mm on the pain visual analogue scale.

Exclusion criteria

* Serious adverse event during the preceding double-blind Protocol A6061026 that was determined to be related to the trial medication by the Investigator. * Patient treatment compliance was less than 80% in the preceding double-blind Protocol A6061026.

Design outcomes

Primary

Measure	Time frame
Physical examination	—
Hematology/Biochemistry	—
Adverse events	—
Vital signs	—
12-lead ECG	—

Secondary

Measure	Time frame
Patient Global Impression of Change	—
Pain Visual Analogue Scale	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026